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Background: In the absence of a gold standard, a panel of experts can be invited to assign a reference diagnosis
for use in research. Available literature offers limited guidance on assembling and working with an expert panel
for this purpose. We aimed to develop a protocol for an expert panel consensus diagnosis and evaluated its
applicability in a pilot project.
Methods: An adjusted Delphi method was used, which started with the assessment of clinical vignettes by 3
experts individually, followed by a consensus discussion meeting to solve diagnostic discrepancies. A panel
facilitator ensured that all experts were able to express their views, and encouraged the use of argumentation to
arrive at a specific diagnosis, until consensus was reached by all experts. Eleven vignettes of patients suspected of
having a primary neurodegenerative disease were presented to the experts. Clinical information was provided
stepwise and included medical history, neurological, physical and cognitive function, brain MRI scan, and follow-up
assessments over 2 years. After the consensus discussion meeting, the procedure was evaluated by the experts.
Results: The average degree of consensus for the reference diagnosis increased from 52% after individual
assessment of the vignettes to 94% after the consensus discussion meeting. Average confidence in the diagnosis
after individual assessment was 85%. This did not increase after the consensus discussion meeting. The process
evaluation led to several recommendations for improvement of the protocol.
Conclusion: A protocol for attaining a reference diagnosis based on expert panel consensus was shown feasible in
research practice.
Keywords: Reference diagnosis, Consensus panel, Delphi, Gold standard, Diagnostic validation, Incorporation bias,
Multidimensional syndromes, Alzheimer’s diseaseBackground
Evidence on diagnostic accuracy is often produced in
cross-sectional studies by comparing the result of a test
under evaluation (the index test, e.g. a newly developed
blood test) with the actual presence or absence of a
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reproduction in any medium, provided the orthe presence of this target condition is available, which is
an error-free classification in all patients, blinded from the
index test result, and performed within a short interval of
time [2]. There are, however, many conditions for which
such a gold standard does not exist. In that case, an alter-
native is then to rely on a clinical reference standard: the
best available way for arriving at a clinical classification.
One option is then to use a panel of experts who, based
on the available information, identify those with the target
condition among the persons being tested [2,3].
An example for a disease for which no test fulfils the
criteria for a gold standard is Alzheimer's disease (AD). It
is defined by a gradual onset of symptoms, deteriorationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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another medical comorbidity or medication that could
affect cognition [4]. An AD diagnosis is traditionally
mainly based on clinical judgement. Recently biomarkers
have been given a prominent role in new diagnostic re-
search criteria for AD [4-6] and require validation [7].
Several reference standards have been discussed for
AD. A post-mortem neuropathological examination has
been criticized for imperfect inter-observer reliability and
imperfect association with cognitive impairment or de-
mentia [8,9]. Another reference standard is to follow up a
patient in the pre-dementia phase until a clinical diagnosis
of AD-type dementia can be made. This requires a long
follow-up period to ensure that all patients with a neuro-
degenerative disease at baseline decline to the level of de-
mentia within that period [10,11].
Several studies have reported on the use of an expert
panel to assign a final diagnosis [12-21]. Most studies
that rely on an expert panel insufficiently described the
rationale behind many of the methodological choices:
the basic approach, the number and choice of experts
that should be invited, the information that must be
supplied to enable expert consensus, the specific questions
to be asked, and how to arrive at consensus. Leaving the
rationale behind many of these elements unknown makes
it difficult to reproduce their findings.
We have developed a protocol for a consensus panel
reference diagnosis in AD based on clinically relevant
decline as judged by a clinician. We evaluated its feasibility
in a pilot project. Based on our findings, we provide a num-
ber of recommendations for other researchers considering
the use of a consensus panel diagnosis.
Methods
Study design
We searched the literature using PubMed for the choices
to be made with regard to the methodology of a consensus
panel diagnosis. Our protocol was then drafted based on
the recommendations from the literature, and tested in a
pilot study.
A panel was composed consisting of 3 clinical experts
(FV, AL and E. Tan MD) with complementary expertise
on neurology, geriatrics and psychiatry. Their clinical
experience ranged from 1 to more than 10 years.
Two diagnoses were set: a care-as-usual diagnosis (ref-
lecting a first visit to a memory clinic) and a reference
diagnosis (the best available way to arrive at a clinical
classification). For both diagnoses an adjusted Delphi
method was applied that started with the assessment of
each case by each expert individually, followed by deter-
mining diagnostic discrepancies. The discrepancies were
then discussed in a consensus meeting between the experts
to resolve the discrepancies. This 3-step approach is graph-
ically presented in Figure 1 and explained below.In the first step, the 3 experts were invited to assess
each of the 11 patient cases individually by logging on to
a web-based questionnaire. In this questionnaire infor-
mation on each case was provided in a staged fashion.
This step consisted of two stages:
1. In stage 1, baseline medical history, neurological and
physical examination findings, psychiatric and clinimetric
assessments, neuropsychological test results, and the re-
sults of an MRI scan were summarized in a vignette in
tabular format. All three experts were asked to individu-
ally answer three questions: 1) “What is the most probable
syndrome for this patient?”, 2) “What is the most probable
aetiology for this patient?” and 3) “What will be the most
likely course of cognitive and/or daily functioning of this
patient within 2 years?” (see Table 1). They also indicated
their level of diagnostic certainty for each question.
2. In stage 2, the experts were asked to individually
answer the same three questions, though now based on
information which included the 2-year follow up of the
symptoms that was added to the information from
stage 1. The same three questions from Table 1 were
asked except the last one “What will be the most likely
course of decline” was rephrased to “what was the course
of decline”.
See Additional file 1 for an example of the available
information to the experts in stage 1 and 2. After each
stage, the answers were frozen and could not be adjusted
retrospectively. No information on biomarkers in cere-
brospinal fluid markers, positron emission tomography
scans, advanced diffusion tensor, or resting state functional
magnetic resonance imaging was provided as this could
result in context bias [22].
In the second step, two independent researchers (RH
and CW) reviewed the responses. All cases for which all
three experts had given identical answers regarding the
syndrome, aetiology and prognosis for stage 1 as well as
stage 2 were identified. Levels of certainty for these cases
were averaged. All cases for which there was no agree-
ment on any of the three questions were forwarded to
the next step.
In the third step, all three experts participated in a
face-to-face panel discussion meeting. For each case, a
summary of the individual answers to the three ques-
tions was presented as well as all relevant clinical
information, identical to the one in the first step. The
experts were invited to express and exchange their
arguments for the answers to the questions and asked
to consider whether, in the light of their colleagues’
assessments, they would like to alter their conclusion.
A panel facilitator ensured that all participants were
able to express their views and encouraged the use of
argumentation to arrive at a specific diagnosis, until
consensus among all experts was reached. No time
limit was set for the discussion.
Figure 1 Process flow of the consensus protocol. Abbreviations: FU, follow-up.
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sis based on the information of stage 1 at the moment
consensus was reached (consensus could have been
reached in step 1 before the discussion meeting, because
the 3 experts scored identical on the web-based ques-
tionnaire, or after the panel discussion meeting in step 3,
because the experts scored different in the web-based
questionnaire of step 1 and required the discussionTable 1 Questionnaire used for rating the vignettes
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1a) What is the most probable syndrome for this patient? Su
M
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1b) How certain are you of this? Co
0%
2a) What is the most probable aetiology for this patient? Al
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2b) How certain are you of this? Co
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3a) In your opinion, what will be the most likely course of
cognitive and/or daily functioning within 2 years?
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3b) How certain are you of this expectation? Co
0%
For the reference diagnosis, question 3a was phrased differently: “In your opinion, what wmeeting to reach consensus). The information at stage 1
represented the information available from a first visit to
a memory clinic: baseline medical history, neurological
and physical examination findings, psychiatric and clini-
metric assessments (see Additional file 1).
The reference diagnosis was defined as the diagnosis
based on the stage 2 information at the moment consensus
was reached (consensus could have been reached beforesponse options
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ild cognitive impairment
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as the course of cognitive and/or daily functioning during the 2-year follow-up?
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sion meeting in step 3). The information at stage 2 con-
tained all available information from stage 1 at baseline
and the 2-year course of symptoms (see Additional file 1).
Afterwards, the experts were asked to complete a
process evaluation questionnaire (see Additional file 2) in
which they were asked about their experiences regarding
the assessment of cases and the consensus discussion,
and were asked to provide feedback and suggestions to
improve the protocol.
Patient population
The cases for the evaluation consisted of a sample of 11
patients who had visited the memory clinic of the
Maastricht University Medical Centre in the Netherlands
in 2009 and 2010 and were suspected of having a primary
neurodegenerative disease according to the following
eligibility criteria [7]: Mini-Mental State Examination
(MMSE) [23] score 20 or higher, Clinical Dementia
Rating (CDR) [24,25] between 0 and 1, and availability
of a reliable informer or proxy. Subjects were excluded
if they had normal pressure hydrocephalus, Huntington’s
disease, transient ischaemic attacks or cerebral vascular
accidents less than 2 years ago, or a previous psychiatric
history. Informed consent was obtained from both the
patient and the informal caregiver. Subjects without any
follow-up assessment (due to refusal or other reasons)
were excluded from this research. The sample was selected
such that it included similar proportions of patients with
subjective memory complaints, mild cognitive impairment
(MCI) and dementia. The hospital’s medical ethics commit-
tee approved this study.
Clinical information
The clinical information included in the vignette (see
Additional file 1 for an example) was based on guidelines
from the American Academy of Neurology [26] and
European Federation of the Neurological Societies [27].
Patient and informant history (medical history, family
history, education, co-morbidities, behavioural and psy-
chological symptoms, and activities of daily living) were
retrieved from an open interview with both patient and
informal caregiver. A neurological and physical examin-
ation, and assessment of co-morbidities was performed
by a clinician. Clinical tests included the MMSE, CDR,
Geriatric Depression Scale-15 (GDS-15) [28], Neuro-
psychiatric Inventory [29] and Disability Assessment for
Dementia (DAD) [30]. Atrophy measurements and white
matter lesions were assessed on 3 T MRI scan images
by a neuroradiologist. Medial temporal lobe atrophy
(MTA) scores, as well as Fazekas scores were used to
quantify hippocampal atrophy and the severity of white
matter lesions. Neuropsychological examination con-
sisted of a battery of cognitive tests administered by aneuropsychologist. Tests included Rey’s Verbal Learning
Test [31,32], Visual Association Test [33], and Digit-Span
[34] to assess memory; Letter Digit Substitution Test [35]
to assess mental processing rate; and Stroop Color-Word
Test [36] and Trail Making Test [37,38] to assess atten-
tion, concentration and interference. Raw scores were
converted to z-scores, adjusted for age, education level
and gender. All assessments took place at baseline and at
12 and 24 months follow-up at the memory clinic, except
the MRI scan which was performed only at baseline.
Statistical analyses
In the analysis we described the care-as-usual and refer-
ence diagnoses that were set, and compared the degree
of consensus before and after the discussion meeting for
the 11 cases. We additionally calculated the average level
of confidence in the diagnostic conclusions.
Results
The baseline patient sample included 8 males and 3
females, with a median age of 78 years (range: 49–86).
The median MMSE score was 28 (range: 22–30), CDR
was 0.5 (range: 0–1) and DAD was 93% (range: 77–100).
The reference syndrome diagnosis was dementia in 5
cases, MCI in 3 cases, and subjective complaints in 3
cases. There was a 100% consensus on the syndromal
diagnosis (see Table 2). Consensus on the reference
aetiology diagnoses was reached in 10 cases (91%).
These included 8 AD cases and 2 patients without neu-
rodegenerative disease. On 1 case no consensus could
be reached (2 experts indicated no neurodegenerative
disease while 1 expert indicated a vascular aetiology). The
reference statement regarding the course of cognitive and
general functioning over time was classified as “improved”
in 1 case, “stable” in 2 cases and “declined” in 7 cases by
all three experts; in 1 case no consensus could be reached.
The degree of consensus over all three questions (syn-
drome, aetiology and disease course) was higher after
the panel consensus meeting (91% for the care-as-usual
and 94% for the reference standard) compared to before
the meeting (70% and 52% respectively). The average
level of confidence in the individually established diag-
noses was 76% for the care-as-usual diagnosis and 85%
for the reference diagnosis. These did not change after
the panel discussion meeting.
It took the experts individually on average 6 minutes
and 6 seconds to assess a case via the internet form, and
8 minutes and 38 seconds to discuss a discrepant case
during the consensus panel meeting.
Table 3 presents the results of the process evaluation
questionnaire. Instructions, procedure and diagnostic
questions were felt to be clear, except for the difference
between the diagnostic question about the expected 2-year
decline that was asked for the care-as-usual diagnosis and
Table 2 Confidence and percentage agreement among experts during individual assessment and consensus discussion
of 11 cases
Item Care-as-usual Reference standard
Before consensus panel
meeting (internet form)
After consensus
panel meeting
Before consensus panel
meeting (internet form)
After consensus
panel meeting
Degree of consensus (average) 70% 91% 52% 94%
Consensus on syndrome 55% 100% 55% 100%
Consensus on aetiology 82% 100% 64% 91%*
Consensus on disease course 73% 73% 36% 91%
Confidence in the diagnoses (average) 76% 76% 85% 85%
*Mixed Alzheimer and vascular aetiology was scored as either of the two, to facilitate consensus with other experts.
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was asked for the reference diagnosis (indicated by 1
expert). Insufficient clinical information was reported
to be available for several reasons: one expert would
have preferred information on clinical history at follow-
up, and two experts stated that they would have liked
to have a ‘real’ clinical picture or to see the patient in
real life. The experts indicated that their reference diag-
nosis was partly influenced by the concluded baseline
care-as-usual diagnosis (diagnostic review bias). Although
none of the panel members felt impeded in expressing
their opinion during the panel discussion meeting, one
expert thought that members had an unequal share in the
discussion. The experts also stated that a 2 year follow-up
period is sometimes insufficient; it is ‘a compromise
between desirable and feasible’ and in an ideal situation
they would prefer a longer period.
During the panel discussion meeting, the experts indi-
cated that they considered the patient’s history information
to be decisive if it contradicted test outcomes of clinical
scales such as MMSE or DAD. They also discussed whatTable 3 Results of the evaluation questionnaire
Item Result
Instructions, procedure and diagnostic questions were clear 92%
Estimated time per case to fill in the internet form 10 minutes
Diagnosis reflects medical practice 100%
Consensus procedure considered valid to determine a
reference diagnosis (scale 0–10)
7.1
Sufficient information available to determine a diagnosis 33%
Influence of baseline diagnosis on reference diagnosis
(scale 0–10)
5.7
All panel members had equal shares in the discussion* 50%
Felt impeded in expressing their opinion 0%
Years of experience needed to participate in an expert
panel (average, range)*
3, 1-5
Two-year follow-up on disease course is sufficient to
determine a reference diagnosis
33%
Three experts is enough 100%
*One expert answered ‘don’t know’ to the this question.extent of decline would be sufficient to mark a case as
‘actual decline’. They indicated that a patient did not
necessarily have to decline to a more severe syndrome,
but could also decline to a clinically relevant lower state of
cognition and/or functioning within a syndrome label.
Discussion
In a pilot study, we tested a 3-step protocol for establish-
ing a consensus panel diagnosis using clinical vignettes
based on 11 cases in the field of cognitive disorders. The
use of an expert panel to attain consensus on a reference
diagnosis was considered feasible in research practice.
Two possible forms of bias can occur in a cohort-
based diagnostic research as applied in this pilot study:
incorporation bias and review bias.
Incorporation bias occurs if information that is used to
establish the care-as-usual or biomarker-driven diagnosis
is also used to establish the reference standard [39]. If for
example a patient’s biomarker profile is available to a
panel of experts who assign the reference diagnosis it
could lead to overestimation of the biomarker’s accuracy,
because the association between biomarker and reference
standard is artificially inflated. This could easily occur
when the standard medical practice diagnosis of AD-type
dementia at follow up is used as a longitudinal reference
standard, because biomarkers are often used in medical
research practice. Many reports on studies that apply such
longitudinal medical practice diagnosis as a reference
standard provide insufficient information on whether the
clinicians were blind for the biomarker results when they
set the medical practice diagnosis after having followed up
a patient [11]. Incorporation bias can also occur when
diagnostic information from care-as-usual is available to
the experts when they assign the reference diagnosis. In
contrast to the inclusion of a patient’s biomarker profile,
as explained above, the care-as-usual baseline information
can hardly be omitted since a starting point is required
for the reference diagnosis (i.e. the level of decline). It
is considered likely that the care-as-usual information
provides a ‘small piece of all available information in-
cluding all follow-ups’ and that the biomarker profile
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judgement’ when experts set the reference diagnosis
[40]. We therefore recommend to incorporate the base-
line clinical information but no biomarker information
in a reference standard.
Review bias may occur in two forms. Test review bias
occurs when the reference diagnosis is known while
either the biomarker-driven or care-as-usual diagnosis is
being set. Vice versa, when either the biomarker-driven
diagnosis or care-as-usual diagnosis is known while the
reference diagnosis is being set it is called diagnostic
review bias [39]. Options 1 and 2 from Figure 2 graph-
ically represent both situations. In an ideal situation, all
three diagnoses are assessed by three independent expert
panels. Due to limited time and resources a decision rule
could be applied that combines the care-as-usual diagno-
sis with the patient’s biomarker profile using pre-defined
cut-off values in a decision rule (see Figure 2 option 3 for
an overview) [2]. From our pilot evaluation questionnaire
(question 16 of Additional file 2) the experts rated poten-
tial review bias an average of 5.7 on a scale of 0 to 10.
Follow-up of pre-dementia patients until a diagnosis of
AD-type dementia is a widely applied reference standard
in validating biomarkers [11]. When using this reference
standard a normal biomarker profile is considered incor-
rect if a pre-dementia patient does not develop AD-type
dementia over time. This approach can lead to an
incorrect classification if this patient declines but not
sufficiently to reach the state of dementia (i.e. theO
pt
io
n 
1
O
pt
io
n 
2
O
pt
io
n 
3
Figure 2 Single panel approach (option 1 and 2) and partly independ
* = possible diagnostic review bias. † = possible test review bias.condition is present but not picked up by the reference
standard). On the opposite, an abnormal biomarker
profile is considered correct if a pre-dementia patient
develops AD-type dementia after a long period of time,
for example in 10 years. This approach can be debated
in case AD pathology was absent when the subject was
tested with the biomarker.
To reduce the extent to which these errors in the ref-
erence standard might occur we considered the concept
of decline itself, instead of decline to the absolute level of
dementia. We do not know what the optimal follow-up
time is to establish decline as a valid reference diagnosis.
In our opinion, the optimal follow-up period is between 3
and 5 years, as the experts indicated that 2 years may
not be sufficient, especially when treatment of cognitive
symptoms, e.g. with cholinesterase inhibitors, is started.
A follow-up longer than 5 years was considered clinically
irrelevant and increase the potential of errors in the refer-
ence standard.
The use of a heterogeneous panel composed of experts
with different backgrounds, though within the area of
interest, has been recommended in the literature [41,42].
Gabel et.al [21] emphasized the importance of selecting
experts who are likely to make different types of errors
of judgment. Heterogeneity of backgrounds could also
help prevent domination by a particular expertise. Other
studies applying a consensus diagnosis have used a
variety of expertise for their expert panel [17,18]. Gabel
et al. [21] found no differences in diagnostic accuracyent approaches (option 3) to evaluate diagnostic tests for AD.
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did not recommend a specific ‘amount’ of required experi-
ence. In our study the experts indicated that between 1
and 5 years of experience in the particular field of expert-
ise was necessary to establish a valid diagnosis.
The limited clinical experience of one of our experts
might be the reason why one of the other panel members
indicated that not everyone had an equal share in the
discussion. Perhaps requiring a larger number of years
of clinical experience might have helped prevent some of
the panel members dominating the discussion. Previous
studies showed a large variety regarding the number of
experts in the panel, though no specific number was
recommended [41,43]. In our study all experts shared
the opinion that having 3 panel members was sufficient
to establish a valid diagnosis. The qualities of the experts
were generally considered more important than the size of
the expert panel group. An uneven number of experts
could facilitate the decision process if a majority vote is
used [3]. Studies reported on in the literature used 2 to 6
experts to determine a consensus diagnosis [13-18,21].
The original Delphi methodology was adjusted in our
project since we did not blind the experts from each
other’s opinion in the panel discussion [15,42]. Since this
might cause bias towards dominant experts, a panel facili-
tator ensured that all participants were enabled to express
their views [21,42]. An alternative, less time–consuming,
method could be to adopt a majority decision after indi-
vidual assessment [13,16,17], which has been reported to
have similar diagnostic accuracy as forced consensus [21].
Most studies suggested that experts should apply medical
practice diagnostic guidelines, though without imposing
strict decision rules.
Video recordings, which could reveal valuable subtle
information on patient history [3], were not provided in
our study, due to limited time and resources. Instead, we
provided a written summary of the clinical history in
which an independent researcher had highlighted the
most important aspects.
Recommendations for adjustments to the protocol
Based on the results of the evaluation questionnaire, a
number of adjustments to the consensus protocol could
be recommended.
 Information on clinical history at follow-up should
be included to arrive at a reference diagnosis.
 A 2-year follow-up period for a reference diagnosis
that should reflect the best available way for arriving
at a clinical classification was considered too short,
though the experts could not provide a specific
period required.
 Experts invited to the panel should have a minimum
of 3 years of clinical experience. In some cases the expert panel concluded after the
group discussion that no consensus could be
reached. As proposed in the literature [13,17], a
majority decision could be adopted in these cases to
prevent inefficient use of discussion time.
 One expert recognized 1 case from the clinic. It is
recommended inviting only experts who have had no
direct interaction with the patients under evaluation.
 Initially we included several non-neurodegenerative
diagnostic options, which resulted in irrelevant
discussions. These were therefore replaced by the
question: ‘No neurodegenerative disease, namely…’.
 The login procedure consisted of several steps.
When implementing this procedure in research
practice, the required time and the complexity of
the procedure should be minimized to maximize the
willingness of experts to devote their time.
The final protocol can be found in Additional file 3.
Limitations
Several limitations apply to this study. Not imposing strict
decision rules allowed for different views within the panel
on how to determine a diagnosis. For example, different
sources of information were used to determine an object-
ive memory deficit to distinguish between subjective
memory complaints and MCI, and some experts always
expected a decline if a neurodegenerative disease was
identified. A preparatory discussion among all experts
might have reduced discussion time and could increase
our understanding of the concept being assessed by the
experts.
Another limitation is that the 3-day period that elapsed
between filling in the internet form and the consensus
panel meeting may have been too short. The experts may
have remembered the follow-up information from the
internet-based questionnaire when discussing the care-
as-usual diagnosis during the consensus panel meeting,
which may have resulted in test review bias.
Although the protocol we developed was a practical
and transparent method to assign a reference diagnosis,
it must be kept in mind that it represents a compromise
between available time and resources versus minimisa-
tion of bias. The optimal design to evaluate a diagnostic
test would be a randomised controlled trial to determine
the effects on patient outcome from undergoing the test
and the actions taken upon the result. Although no
disease-modifying therapies in the pre-dementia phase
are available for AD, there is still an interest in the
validity of new biomarkers to distinguish disease from
non-disease or to enable future planning for patients.
When such treatments become available, evidence on
the level of diagnostic accuracy can strengthen clinical
decision-making [44,45].
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Our aim was to assess the feasibility of establishing a
consensus panel diagnosis, for the purpose of studies
into cognitive decline and AD, and to establish a proto-
col for such a consensus panel diagnosis. The protocol
was evaluated in a pilot study and the results indicate
that this protocol was feasible in research practice.
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Additional file 2: Evaluation questionnaire.
Additional file 3: Final proposed protocol.
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